期刊
CANCER VACCINES
卷 1174, 期 -, 页码 88-98出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2009.05000.x
关键词
dendritic cells; cancer; vaccines; priming
资金
- National Institutes of Health [P01 CA084514, R01 CA089440, CA078846]
- Dana Foundation
- Susan Komen Foundation
- Baylor Health Care System
- Baylor Health Care System Foundation
- NATIONAL CANCER INSTITUTE [R01CA089440, R01CA078846, R01CA140602, P01CA084512] Funding Source: NIH RePORTER
Passive immunotherapy of cancer (i.e., transfer of T cells or antibodies) can lead to some objective clinical responses, thus demonstrating that the immune system can reject tumors. However, passive immunotherapy is not expected to yield memory T cells that might control tumor outgrowth. Active immunotherapy with dendritic cell (DC) vaccines has the potential to induce tumor-specific effector and memory T cells. Clinical trials testing first-generation DC vaccines pulsed with tumor antigens provided a proof-of-principle that therapeutic immunity can be elicited. Newer generation DC vaccines are built on the increased knowledge of the DC system, including the existence of distinct DC subsets and their plasticity all leading to the generation of distinct types of immunity. Rather than the quantity of IFN-gamma-secreting CD8(+) T cells, we should aim at generating high-quality, high-avidity, polyfunctional effector CD8(+) T cells able to reject tumors and long-lived memory CD8(+) T cells able to prevent relapse.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据